We are Sorry, This Page doesn't Exist
Analysts Unfazed By FDA Snub Of Sarepta"s DMD Drug, Pin Hopes On Gene Therapy
Sarepta Therapeutics Inc (NASDAQ: SRPT)'s new drug application for its second Duchenne muscular dystrophy drug received.....»»
Sarepta Hits Record High As Duchenne Muscular Dystrophy Gene Therapy Yields Positive Results In Early-Stage Study
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares, halted shortly before Tuesday's open, opened higher by more than 50 percent. read more.....»»
Analyst: Sarepta"s DMD Gene Therapy Results "Dramatic And Far Exceeding Expectations"
Sarepta Therapeutics Inc. (NASDAQ: SRPT) reported some encouragi.....»»
FDA Lifts Clinical Hold on Sarepta"s DMD Gene Therapy Program
The FDA has lifted clinical hold on Sarepta's (SRPT) cl.....»»
Sarepta, Lysogene Announce Exclusive License Agreement for LYS - SAF302, a Late- stage Gene Therapy for the Treatment of MPS IIIA; Grant of Option Rights to an Additional CNS Gene Therapy Candidate
Sarepta Therapeutics, Inc. read more.....»»
Janney, Morgan Stanley Say Sarepta"s Gene Therapy Remains On Track
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares were under pressure this week following a regulatory update that analysts say may have been misunderstood by the market. Latest Ratings for .....»»
Sio Gene Therapies" GM1 Gangliosidosis Gene Therapy Candidate Shows Substrate Reduction In CSF
read more.....»»
The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 7) read more.....»»
Morgan Stanley downgrades Sarepta to Equal Weight after DMD gene therapy miss
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Before the Move: Watch Sarepta ahead of Duchenne gene therapy data
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
After Pfizer data, Goldman says Sarepta remains "leader" in DMD gene therapy
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Sarepta jumps after Pfizer announces DMD gene therapy data
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Sarepta, Dyno Therapeutics to develop gene therapy vectors for muscle diseases
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Sarepta CEO Doug Ingram on gene therapy for DMD
The following.....»»
Gene therapy invented at Nationwide Children"s lands $1.1B commercialization deal for Boston biotech
A gene therapy invented at Nationwide Children's Hospital just landed a licensing deal worth as much as $2.8 billion for a Boston biotech, and now the company's Columbus office will play a big role in getting the treatment to the market. Sarepta Th.....»»
Sarepta DMD gene therapy worth at least $90 per share, says Bernstein
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Why This Duchenne Muscular Dystropy Deal Could Be Huge
Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for its investigational gene therapy for Duchenne muscular dystrophy......»»
Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal
Roche Holding AG made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States......»»
Sarepta"s "transformative" Roche deal validates DMD gene therapy, says Baird
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Roche enters $1.15 billion licensing deal for Sarepta gene therapy
Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta's investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States......»»